Hiroyoshi Nishikawa

List of Publications by Year
in descending order

136 papers	17,314 citations	44042 48 h-index	16164 124 g-index
143 all docs	143 docs citations	143 times ranked	23755 citing authors

#	Article	IF	Citations
1	Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature, 2013, 500, 232-236.	13.7	2,339
2	Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 18538-18543.	3.3	2,100
3	Regulatory T cells in cancer immunosuppression â€" implications for anticancer therapy. Nature Reviews Clinical Oncology, 2019, 16, 356-371.	12.5	872
4	Regulatory T cells in tumor immunity. International Journal of Cancer, 2010, 127, 759-767.	2.3	749
5	PD-1$^+$regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 9999-10008.	3.3	655
6	Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers. Nature Medicine, 2016, 22, 679-684.	15.2	641
7	Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?. Cancer Science, 2019, 110, 2080-2089.	1.7	614
8	Regulatory T cells in cancer immunotherapy. Current Opinion in Immunology, 2014, 27, 1-7.	2.4	612
9	Anti-CCR4 mAb selectively depletes effector-type FoxP3$^+$ CD4$^+$ regulatory T cells, evoking antitumor immune responses in humans. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 17945-17950.	3.3	556
10	Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603). Journal of Clinical Oncology, 2020, 38, 2053-2061.	0.8	469
11	Interleukin-10-Producing Plasmablasts Exert Regulatory Function in Autoimmune Inflammation. Immunity, 2014, 41, 1040-1051.	6.6	450
12	The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nature Immunology, 2020, 21, 1346-1358.	7.0	431
13	Roles of regulatory T cells in cancer immunity. International Immunology, 2016, 28, 401-409.	1.8	412
14	NYâ€ESOâ€1: Review of an Immunogenic Tumor Antigen. Advances in Cancer Research, 2006, 95, 1-30.	1.9	311
15	Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut. Blood, 2016, 128, 2083-2088.	0.6	279
16	Lactic acid promotes PD-1 expression in regulatory TÂcells in highly glycolytic tumor microenvironments. Cancer Cell, 2022, 40, 201-218.e9.	7.7	266
17	Natural and Induced T Regulatory Cells in Cancer. Frontiers in Immunology, 2013, 4, 190.	2.2	202
18	Tumorâ€infiltrating ILâ€17â€producing Î³Î´ T cells support the progression of tumor by promoting angiogenesis. European Journal of Immunology, 2010, 40, 1927-1937.	1.6	200

#	Article	IF	Citations
19	Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients. Clinical Cancer Research, 2015, 21, 4327-4336.	3.2	187
20	Regulatory T cells: a potential target in cancer immunotherapy. Annals of the New York Academy of Sciences, 2018, 1417, 104-115.	1.8	184
21	Sialyl Lewis x (CD15s) identifies highly differentiated and most suppressive FOXP3 high regulatory T cells in humans. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 7225-7230.	3.3	164
22	In vivo antigen delivery by aSalmonella typhimurium type III secretion system for therapeutic cancer vaccines. Journal of Clinical Investigation, 2006, 116, 1946-1954.	3.9	164
23	Detection of self-reactive CD8 + T cells with an anergic phenotype in healthy individuals. Science, 2014, 346, 1536-1540.	6.0	162
24	CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients. Blood, 2005, 106, 1008-1011.	0.6	160
25	Blockade of EGFR improves responsiveness to PD-1 blockade in *EGFR* -mutated non–small cell lung cancer. Science Immunology, 2020, 5, .	5.6	160
26	CD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 10902-10906.	3.3	152
27	Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti–CTLA-4 antibody. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 609-618.	3.3	141
28	Antitumour immunity regulated by aberrant ERBB family signalling. Nature Reviews Cancer, 2021, 21, 181-197.	12.8	141
29	Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment. , 2018, 6, 106.		138
30	Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 165-174.	1.8	123
31	An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells. Immunity, 2020, 53, 187-203.e8.	6.6	119
32	Definition of target antigens for naturally occurring CD4+ CD25+ regulatory T cells. Journal of Experimental Medicine, 2005, 201, 681-686.	4.2	118
33	Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals. Clinical Cancer Research, 2010, 16, 2781-2791.	3.2	118
34	A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors. Clinical Cancer Research, 2019, 25, 6614-6622.	3.2	106
35	Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies. , 2021, 9, e002591.		105
36	Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 9253-9257.	3.3	102

#	Article	IF	Citations
37	ICOS⁺Foxp3⁺TILs in gastric cancer are prognostic markers and effector regulatory T cells associated with *H**elicobacter pylori*. International Journal of Cancer, 2017, 140, 686-695.	2.3	100
38	IFN-γ Controls the Generation/Activation of CD4+CD25+ Regulatory T Cells in Antitumor Immune Response. Journal of Immunology, 2005, 175, 4433-4440.	0.4	92
39	Detection of T cell responses to a ubiquitous cellular protein in autoimmune disease. Science, 2014, 346, 363-368.	6.0	86
40	Selective inhibition of low-affinity memory CD8+ T cells by corticosteroids. Journal of Experimental Medicine, 2019, 216, 2701-2713.	4.2	82
41	Regulatory T Cell–Resistant CD8+ T Cells Induced by Glucocorticoid-Induced Tumor Necrosis Factor Receptor Signaling. Cancer Research, 2008, 68, 5948-5954.	0.4	80
42	The critical role of CD4+ T cells in PD-1 blockade against MHC-II–expressing tumors such as classic Hodgkin lymphoma. Blood Advances, 2020, 4, 4069-4082.	2.5	76
43	Clinical response to PD-1 blockade correlates with a sub-fraction of peripheral central memory CD4+ T cells in patients with malignant melanoma. International Immunology, 2018, 30, 13-22.	1.8	74
44	Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity. Clinical Cancer Research, 2019, 25, 4808-4819.	3.2	66
45	Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma. Blood, 2012, 119, 3097-3104.	0.6	65
46	Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape. Science Immunology, 2021, 6, eabc6424.	5.6	64
47	Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability–High Locally Advanced Rectal Cancer. Clinical Cancer Research, 2022, 28, 1136-1146.	3.2	62
48	Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan. Haematologica, 2018, 103, 1835-1842.	1.7	59
49	Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells. Journal of Experimental Medicine, 2020, 217, .	4.2	58
50	Peptide-pulsed dendritic cell vaccination targeting interleukin-13 receptor α2 chain in recurrent malignant glioma patients with HLA-A*24/A*02 allele. Cytotherapy, 2012, 14, 733-742.	0.3	56
51	Influence of CD4+CD25+ Regulatory T Cells on Low/High-Avidity CD4+ T Cells following Peptide Vaccination. Journal of Immunology, 2006, 176, 6340-6346.	0.4	52
52	NY–CO–58/KIF2C is overexpressed in a variety of solid tumors and induces frequent T cell responses in patients with colorectal cancer. International Journal of Cancer, 2010, 127, 381-393.	2.3	52
53	Transcriptional regulatory network for the establishment of CD8+ T cell exhaustion. Experimental and Molecular Medicine, 2021, 53, 202-209.	3.2	51
54	Regulatory T Cells: Molecular and Cellular Basis for Immunoregulation. Current Topics in Microbiology and Immunology, 2017, 410, 3-27.	0.7	48

#	Article	IF	Citations
55	Clinical impact of pre-transplant gut microbial diversity on outcomes of allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 2017, 96, 1517-1523.	0.8	48
56	Peptide Vaccine Induces Enhanced Tumor Growth Associated with Apoptosis Induction in CD8+ T Cells. Journal of Immunology, 2010, 185, 3768-3776.	0.4	47
57	CD4 $^{+}$ T cells are essential for the development of destructive thyroiditis induced by anti–PD-1 antibody in thyroglobulin-immunized mice. Science Translational Medicine, 2021, 13, .	5.8	47
58	A mixture-of-experts deep generative model for integrated analysis of single-cell multiomics data. Cell Reports Methods, 2021, 1, 100071.	1.4	47
59	Intracellular Tumor-Associated Antigens Represent Effective Targets for Passive Immunotherapy. Cancer Research, 2012, 72, 1672-1682.	0.4	46
60	Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein–Barr virus status, and cancer genome alterations in metastatic gastric cancer. Gastric Cancer, 2019, 22, 69-76.	2.7	45
61	PD-1 blockade therapy promotes infiltration of tumor-attacking exhausted T cell clonotypes. Cell Reports, 2022, 38, 110331.	2.9	45
62	Multicenter Phase I/II Trial of Napabucasin and Pembrolizumab in Patients with Metastatic Colorectal Cancer (EPOC1503/SCOOP Trial). Clinical Cancer Research, 2020, 26, 5887-5894.	3.2	44
63	The Soluble Notch Ligand, Jagged-1, Inhibits Proliferation of CD34+ Macrophage Progenitors. International Journal of Hematology, 2002, 75, 269-276.	0.7	40
64	Vaginal Transmission of Cancer from Mothers with Cervical Cancer to Infants. New England Journal of Medicine, 2021, 384, 42-50.	13.9	40
65	Heteroclitic serological response in esophageal and prostate cancer patients after NY–ESO–1 protein vaccination. International Journal of Cancer, 2012, 130, 584-592.	2.3	38
66	Thioredoxin suppresses airway inflammation independently of systemic Th1/Th2 immune modulation. European Journal of Immunology, 2010, 40, 787-796.	1.6	37
67	Identification of Tumoricidal TCRs from Tumor-Infiltrating Lymphocytes by Single-Cell Analysis. Cancer Immunology Research, 2018, 6, 378-388.	1.6	35
68	Glucocorticoid–induced tumor necrosis factor receptor stimulation enhances the multifunctionality of adoptively transferred tumor antigen–specific CD8 $^{+}$ T cells with tumor regression. Cancer Science, 2009, 100, 1317-1325.	1.7	34
69	IFN-γ-dependent type 1 immunity is crucial for immunosurveillance against squamous cell carcinoma in a novel mouse carcinogenesis model. Carcinogenesis, 2009, 30, 1408-1415.	1.3	33
70	TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment. , 2022, 9, e003134.		32
71	Antibody-based therapy in colorectal cancer. Immunotherapy, 2013, 5, 533-545.	1.0	31
72	Induction of regulatory T cell–resistant helper CD4+ T cells by bacterial vector. Blood, 2008, 111, 1404-1412.	0.6	28

#	Article	IF	Citations
73	HLA Class I Analysis Provides Insight Into the Genetic and Epigenetic Background of Immune Evasion in Colorectal Cancer With High Microsatellite Instability. Gastroenterology, 2022, 162, 799-812.	0.6	28
74	Induction of CD8 T‑cell responses restricted to multiple HLA class I alleles in a cancer patient by immunization with a 20‑mer NY‑ESO‑1f (NY‑ESO‑1 91‑110) peptide. International Journal of Cancer, 2013, 132, 345-354.	2.3	27
75	Activities of granulocyte-macrophage colony-stimulating factor and interleukin-3 on monocytes. American Journal of Hematology, 2004, 75, 179-189.	2.0	25
76	Tax is a potential molecular target for immunotherapy of adult <scp>T</scp>‑cell leukemia/lymphoma. Cancer Science, 2012, 103, 1764-1773.	1.7	23
77	Effector Regulatory T Cells Reflect the Equilibrium between Antitumor Immunity and Autoimmunity in Adult T-cell Leukemia. Cancer Immunology Research, 2016, 4, 644-649.	1.6	23
78	Efficient ex vivo generation of dendritic cells from CD14+ blood monocytes in the presence of human serum albumin for use in clinical vaccine trials. British Journal of Haematology, 2001, 114, 681-689.	1.2	22
79	Vescimonas gen. nov., Vescimonas coprocola sp. nov., Vescimonas fastidiosa sp. nov., Pusillimonas gen. nov. and Pusillimonas faecalis sp. nov. isolated from human faeces. International Journal of Systematic and Evolutionary Microbiology, 2021, 71, .	0.8	21
80	Hypomethylation of the Treg-Specific Demethylated Region in <i>FOXP3</i> Is a Hallmark of the Regulatory T-cell Subtype in Adult T-cell Leukemia. Cancer Immunology Research, 2016, 4, 136-145.	1.6	20
81	Enhanced tumor response to radiotherapy after PD-1 blockade in metastatic gastric cancer. Gastric Cancer, 2020, 23, 893-903.	2.7	20
82	Engineering strategies for broad application of TCR-T- and CAR-T-cell therapies. International Immunology, 2021, 33, 551-562.	1.8	20
83	TAS-116 (Pimitespib), an Oral HSP90 Inhibitor, in Combination with Nivolumab in Patients with Colorectal Cancer and Other Solid Tumors: An Open-Label, Dose-Finding, and Expansion Phase Ib Trial (EPOC1704). Clinical Cancer Research, 2021, 27, 6709-6715.	3.2	20
84	De novo CD5-positive Diffuse Large B-cell Lymphoma of the Temporal Bone Presenting with an External Auditory Canal Tumor. Internal Medicine, 2006, 45, 733-737.	0.3	19
85	UV irradiation of immunized mice induces type 1 regulatory T cells that suppress tumor antigen specific cytotoxic T lymphocyte responses. International Journal of Cancer, 2011, 129, 1126-1136.	2.3	19
86	Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal. , 2021, 9, e002279.		19
87	ï¼œEditors' Choiceï¼ž Meddling with meddlers: curbing regulatory T cells and augmenting antitumor immunity. Nagoya Journal of Medical Science, 2019, 81, 1-18.	0.6	18
88	A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer. Gastric Cancer, 2022, 25, 619-628.	2.7	18
89	Potentiality of multiple modalities for single-cell analyses to evaluate the tumor microenvironment in clinical specimens. Scientific Reports, 2021, 11, 341.	1.6	17
90	Importance of lymph node immune responses in MSI-H/dMMR colorectal cancer. JCI Insight, 2021, 6, .	2.3	17

#	Article	IF	Citations
91	Meflin-positive cancer-associated fibroblasts enhance tumor response to immune checkpoint blockade. Life Science Alliance, 2022, 5, e202101230.	1.3	16
92	Antibody to CMRF35-Like Molecule 2, CD300e A Novel Biomarker Detected in Patients with Fulminant Type 1 Diabetes. PLoS ONE, 2016, 11, e0160576.	1.1	15
93	Analysis of the Tumor Reactivity of Tumor-Infiltrating Lymphocytes in a Metastatic Melanoma Lesion that Lost Major Histocompatibility Complex Class I Expression after Anti–PD-1 Therapy. Journal of Investigative Dermatology, 2019, 139, 1490-1496.	0.3	15
94	Classification of idiopathic interstitial pneumonias using anti–myxovirus resistance-protein 1 autoantibody. Scientific Reports, 2017, 7, 43201.	1.6	14
95	<scp>HSP90</scp> inhibition overcomes <scp><i>EGFR</i></scp> amplification–induced resistance to third–generation <scp>EGFR–TKIs</scp>. Thoracic Cancer, 2021, 12, 631-642.	0.8	14
96	Novel anti-GARP antibody DS-1055a augments anti-tumor immunity by depleting highly suppressive GARP+ regulatory T cells. International Immunology, 2021, 33, 435-446.	1.8	14
97	Clinicopathological, genomic and immunological features of hyperprogressive disease during PD-1 blockade in gastric cancer patients.. Journal of Clinical Oncology, 2018, 36, 4106-4106.	0.8	14
98	Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma. Haematologica, 2022, 107, 2418-2431.	1.7	14
99	Human bone marrow stromal cells simultaneously support <scp>B</scp> and <scp>T</scp>/<scp>NK</scp> lineage development from human haematopoietic progenitors: a principal role for flt3 ligand in lymphopoiesis. British Journal of Haematology, 2012, 157, 674-686.	1.2	12
100	Adult-Onset Anti-Citrullinated Peptide Antibody-Negative Destructive Rheumatoid Arthritis Is Characterized by a Disease-Specific CD8+ T Lymphocyte Signature. Frontiers in Immunology, 2020, 11, 578848.	2.2	11
101	Depletion of central memory CD8+ T cells might impede the antitumor therapeutic effect of Mogamulizumab. Nature Communications, 2021, 12, 7280.	5.8	11
102	Model-based cell clustering and population tracking for time-series flow cytometry data. BMC Bioinformatics, 2019, 20, 633.	1.2	10
103	The potential application of PD-1 blockade therapy for early-stage biliary tract cancer. International Immunology, 2020, 32, 273-281.	1.8	10
104	Suppression from beyond the grave. Nature Immunology, 2017, 18, 1285-1286.	7.0	10
105	The ratio of CD8 + lymphocytes to tumor-infiltrating suppressive FOXP3 + effector regulatory T cells is associated with treatment response in invasive breast cancer. Discover Oncology, 2022, 13, 27.	0.8	10
106	Identification of Novel and Noninvasive Biomarkers of Acute Cellular Rejection After Liver Transplantation by Protein Microarray. Transplantation Direct, 2016, 2, e118.	0.8	9
107	Regulatory T cells, as a target in anticancer immunotherapy. Immunotherapy, 2017, 9, 623-627.	1.0	9
108	Overcoming regulatory T–cell suppression by a lyophilized preparation of <i>Streptococcus pyogenes</i>. European Journal of Immunology, 2013, 43, 989-1000.	1.6	8

#	Article	IF	Citations
109	Endoscopic Activity and Serum TNF-Î± Level at Baseline Are Associated With Clinical Response to Ustekinumab in Crohnâ€™s Disease Patients. Inflammatory Bowel Diseases, 2020, 26, 1669-1681.	0.9	8
110	Updated Efficacy Outcomes of Anti-PD-1 Antibodies plus Multikinase Inhibitors for Patients with Advanced Gastric Cancer with or without Liver Metastases in Clinical Trials. Clinical Cancer Research, 2022, 28, 3480-3488.	3.2	8
111	Immunosuppressive tumor microenvironment of usual interstitial pneumonia-associated squamous cell carcinoma of the lung. Journal of Cancer Research and Clinical Oncology, 2018, 144, 835-844.	1.2	7
112	Report on the use of nonâ€clinical studies in the regulatory evaluation of oncology drugs. Cancer Science, 2016, 107, 189-202.	1.7	6
113	Phase Ib study on the humanized anti-CCR4 antibody, KW-0761, in advanced solid tumors.. Nagoya Journal of Medical Science, 2021, 83, 827-840.	0.6	6
114	NYâ€ESOâ€1 protein glycosylated by yeast induces enhanced immune responses. Yeast, 2010, 27, 919-931.	0.8	5
115	Overview: New Modality for Cancer Treatment. Oncology, 2015, 89, 33-35.	0.9	5
116	Study protocol for JCOG1807C (DEEP OCEAN): a interventional prospective trial to evaluate the efficacy and safety of durvalumab before and after operation or durvalumab as maintenance therapy after chemoradiotherapy against superior sulcus non-small cell lung cancer. Japanese Journal of Clinical Oncology, 2022, 52, 383-387.	0.6	5
117	Newly emerged immunogenic neoantigens in established tumors enable hosts to regain immunosurveillance in a T-cell-dependent manner. International Immunology, 2021, 33, 39-48.	1.8	4
118	Regulatory T cells in cancer; can they be controlled?. Immunotherapy, 2015, 7, 843-846.	1.0	3
119	Regulatory T Cell as a Biomarker of Treatment-Free Remission in Patients with Chronic Myeloid Leukemia. Cancers, 2021, 13, 5904.	1.7	3
120	Isolation of tumor-infiltrating lymphocytes from preserved human tumor tissue specimens for downstream characterization. STAR Protocols, 2022, 3, 101557.	0.5	3
121	Characterization of the tumor immune-microenvironment of lung adenocarcinoma associated with usual interstitial pneumonia. Lung Cancer, 2018, 126, 162-169.	0.9	2
122	Tyrosine Kinase Inhibitor Imatinib Enhances Tumor Immunity By Depleting Functionally Mature Regulatory T Cells. Blood, 2015, 126, 2219-2219.	0.6	2
123	Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune Infiltration. Cancer Research Communications, 2022, 2, 739-753.	0.7	2
124	Comprehensive exploration of autoantibody in BehÃ§et's disease: A novel autoantibody to claudin-1, an essential protein for tight junctions, is identified. Joint Bone Spine, 2014, 81, 546-548.	0.8	1
125	Flow cytometry analysis of peripheral Tregs in patients with multiple myeloma under lenalidomide maintenance. International Journal of Hematology, 2021, 113, 772-774.	0.7	1
126	CYBERTRACK2.0: zero-inflated model-based cell clustering and population tracking method for longitudinal mass cytometry data. Bioinformatics, 2021, 37, 1632-1634.	1.8	1

#	Article	IF	Citations
127	Regulatory T cells as a target of cancer immunotherapy. Annals of Oncology, 2016, 27, vii3.	0.6	0
128	Analysis of CCR4-expressing T cells in patients with rhododenol-induced leukoderma. Journal of Dermatological Science, 2016, 84, e13.	1.0	0
129	Possible Biomarker for immune checkpoint inhibitor. Annals of Oncology, 2017, 28, ix20.	0.6	0
130	A simple method to distinguish residual elotuzumab from monoclonal paraprotein in immunofixation assays for multiple myeloma patients. International Journal of Hematology, 2021, 113, 473-479.	0.7	0
131	Kinetics of Regulatory T Cells Predict the Recurrence of CML after Stopping Imatinib in Japanese CML Patiens. Blood, 2016, 128, 4240-4240.	0.6	0
132	Clinical Impact of Pre-Transplant Microbial Diversity on Transplant Outcomes. Blood, 2016, 128, 4577-4577.	0.6	0
133	Regulatory-T cells (Tregs) in tumor infiltrating lymphocytes (TILs) from patients with advanced gastric cancer (AGC) after chemotherapy containing ramucirumab.. Journal of Clinical Oncology, 2017, 35, e15570-e15570.	0.8	0
134	Internal Medicine, 2019, 108, 430-437.	0.0	0
135	Optimum Imatinib Exposure Have Possibility of Leading to Appropriate Immune Response after Imatinib Discontinuation in CML Patients. Blood, 2019, 134, 192-192.	0.6	0
136	Correlation between Changes in Granzyme B Expression and Time to Progression in Patients with Newly Diagnosed Multiple Myeloma Treated with Lenalidomide and Dexamethasone Therapy. Blood, 2019, 134, 1792-1792.	0.6	0